Loading...
IVA logo

Inventiva S.A.NasdaqGM:IVA Stock Report

Market Cap US$1.0b
Share Price
n/a
1Y30.1%
7D19.0%
1D-3.7%
Portfolio Value
​
View

Inventiva S.A.

NasdaqGM:IVA Stock Report

Market Cap: US$1.0b

Inventiva (IVA) Stock Overview

A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. More details

IVA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth3/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Rewards

Revenue is forecast to grow 51.32% per year

Risk Analysis

Negative shareholders equity

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years


IVA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW484,853 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
484,853 investors already sharing narratives
View all narratives

Inventiva S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Inventiva
Historical stock prices
Current Share Price€4.39
52 Week High€7.98
52 Week Low€2.85
Beta0.89
1 Month Change12.28%
3 Month Change-20.18%
1 Year Change30.10%
3 Year Change4.28%
5 Year Change-68.58%
Change since IPO-67.29%

Recent News & Updates

Seeking Alpha • May 15

Inventiva's Speculative Upside Through MASH Is Promising

Summary Inventiva is now essentially a lanifibranor bet. Their prospects hinge on the upcoming Phase 3 NATiV3 readout, which we should get by Q4 2026. In my view, lanifibranor seems relatively differentiated after its Phase 2b results. Management is narrowing its focus solely on this MASH asset. IVA’s balance sheet has sufficient financing to reach that readout. But please bear in mind that it’s a binary outcome. I believe that, if lanifibranor succeeds, the upside could be considerable. Conversely, if they fail, their runway would be tighter with a failed asset. On balance, IVA is the quintessential high-risk, high-reward biotech stock. But, given its promising trial data, the setup is compelling. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • May 15

Inventiva's Speculative Upside Through MASH Is Promising

Summary Inventiva is now essentially a lanifibranor bet. Their prospects hinge on the upcoming Phase 3 NATiV3 readout, which we should get by Q4 2026. In my view, lanifibranor seems relatively differentiated after its Phase 2b results. Management is narrowing its focus solely on this MASH asset. IVA’s balance sheet has sufficient financing to reach that readout. But please bear in mind that it’s a binary outcome. I believe that, if lanifibranor succeeds, the upside could be considerable. Conversely, if they fail, their runway would be tighter with a failed asset. On balance, IVA is the quintessential high-risk, high-reward biotech stock. But, given its promising trial data, the setup is compelling. Read the full article on Seeking Alpha
Seeking Alpha • Jul 08

Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement

Summary Inventiva S.A. top-line results from phase 3 NATiV3 study, using lanifibranor for the treatment of patients with MASH, expected by 2nd half of 2026. The 4th pass of the safety review of the DMC was conducted, and it was noted that the phase 3 NATiV3 study should continue without modification. The global non-alcoholic steatohepatitis market is expected to reach $48.3 billion by the end of 2035. It could compete against other MASH companies with the use of lanifibranor by establishing several competitive advantages or by combining it with GLP-1 drugs. Read the full article on Seeking Alpha
Seeking Alpha • Feb 22

Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause

Summary Enrollment pause in phase III NATiV3 study, using lanifibranor for the treatment of patients with NASH, only expected to last 4 to 6 weeks; Trial to continue on with protocol amendments. Publication of results from phase IIa LEGEND study, using lanifibranor in combination with Jardiance for the treatment of patients with NASH and Type 2 Diabetes, expected Q1 of 2024. The global non-alcoholic steatohepatitis treatment market size is expected to reach $48.3 billion by the end of 2035. Several competitors in NASH, but the company might overcome most with the fact that oral administration can be given; Another option to beat the competition would be through combination treatments such as lanifibranor + Jardiance. Read the full article on Seeking Alpha
Seeking Alpha • Sep 21

Inventiva, Sino Biopharm sign licensing pact to develop, commercialize NASH treatment

France-based clinical-stage biopharma Inventiva (NASDAQ:IVA) on Wednesday said it had entered into a licensing and collaboration agreement with a unit of Chinese pharmaceutical group Sino Biopharm for its non-alcoholic steatohepatitis (NASH) treatment lanifibranor. As per the deal, Inventiva (IVA) will get a $12M upfront payment along with $5M in short term potential milestone payments. IVA will also be eligible to get up to $290M in clinical, regulatory and commercial milestone payments, in addition to tiered royalties. Sino Biopharm will oversee the development and commercialization of lanifibranor in Greater China, IVA said in a statement. IVA's lanifibranor had previously received a breakthrough therapy designation from the U.S. FDA. U.S.-listed shares of IVA -2.8% to $3.82 after hours.

Shareholder Returns

IVAUS BiotechsUS Market
7D19.0%4.0%-0.7%
1Y30.1%42.5%20.3%

Return vs Industry: IVA underperformed the US Biotechs industry which returned 42.5% over the past year.

Return vs Market: IVA exceeded the US Market which returned 20.3% over the past year.

Price Volatility

Is IVA's price volatile compared to industry and market?
IVA volatility
IVA Average Weekly Movement10.4%
Biotechs Industry Average Movement10.4%
Market Average Movement7.3%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: IVA has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: IVA's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201173Andrew Obenshaininventivapharma.com

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis.

Inventiva S.A. Fundamentals Summary

How do Inventiva's earnings and revenue compare to its market cap?
IVA fundamental statistics
Market capUS$1.02b
Earnings (TTM)-US$404.64m
Revenue (TTM)US$7.73m
131.4x
P/S Ratio
-2.5x
P/E Ratio

Is IVA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IVA income statement (TTM)
Revenue€6.76m
Cost of Revenue€22.00k
Gross Profit€6.74m
Other Expenses€360.88m
Earnings-€354.14m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

Sep 25, 2026

Earnings per share (EPS)-1.50
Gross Margin99.67%
Net Profit Margin-5,237.95%
Debt/Equity Ratio-799.8%

How did IVA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/08 23:57
End of Day Share Price 2026/07/08 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Inventiva S.A. is covered by 22 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eliana MerleBarclays
Edward NashCanaccord Genuity
Etzer DaroutGuggenheim Securities, LLC